3SBio Inc.Shenyang, China (NASDAQ (GM): SSRX)

Biotechs Working on Anthrax Vaccine - The US government has awarded nearly $110 million in contracts for continuing work on genetically engineered anthrax vaccines. The money is part of an ongoing effort to build up the Strategic National Stockpile of anthrax vaccine doses to 25 million. The two biotechnology companies that will receive the funds are Emergent BioSolutions, which is already supplying a form of anthrax vaccine, and PharmAthene.

Genetically Modified Meat Near - FDA is accepting comments on proposed guidelines to allow genetically modified (GM) animals to be processed and sold as food, something the biotech industry largely supports. For years, the issue has been controversial among consumer groups, which are unhappy that FDA's proposed rules don't require different labeling for GM meat. FDA will, however, have to approve all GM animal products, and will review both animal and human safety issues prior to approval.

Money Tight, but Biotechs Continue On - Recent news that biotech firm MacroGenics secured $25 million to fund ongoing research on its cancer treatments is proof, according to industry experts, that biotechs can still prosper despite the challenging US economic climate. Among the biotech sectors' advantages are their link to the healthcare industry, which is still performing well. However, experts note that recent investment bank consolidation may force smaller biotech firms to work harder to find funding deals.